Apitegromab FDA Approval: First Muscle-Targeted SMA Add-On Faces $310K Payer Gauntlet With Dose-Specific Efficacy Caveat

FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

The FDA has approved Scholar Rock's apitegromab, marketed as Isembyld, for spinal muscular atrophy (SMA) in adults and children aged two years and older. This approval, granted on September 11, 2026, positions Isembyld as the first "muscle-targeted" treatment for SMA, to be used alongside existing therapies. The drug, which blocks myostatin to promote muscle growth, demonstrated significant improvements in motor function during clinical testing. Despite a previous rejection in September 2025 due to manufacturing facility issues, Scholar Rock successfully resolved these concerns, leading to the current clearance. The annual list price for Isembyld is approximately $310,000.

• Isembyld represents a therapeutic breakthrough as the first "muscle-targeted" treatment for SMA. Its mechanism involves blocking myostatin, a protein that limits muscle growth, thereby promoting muscle development. Clinical testing demonstrated that Isembyld significantly improved motor function when administered alongside standard therapies, addressing a critical unmet need for patients experiencing motor function decline despite existing treatments.
• The FDA's approval on September 11, 2026, marks a significant achievement for Scholar Rock, especially after the drug faced a rejection in September 2025 due to manufacturing facility issues. The company successfully navigated these challenges by implementing an alternative production plan. Analysts project Isembyld could achieve approximately $2 billion in peak annual sales, underscoring its substantial market potential and Scholar Rock's ambition to become a major independent biopharma company.
• Isembyld is approved for a broad population, including adults and children aged two years and older with SMA, for use in conjunction with other targeted therapies. The annual list price is set around $310,000, with variations based on patient weight and insurance. The prescribing information includes a warning regarding an increased risk of bone fractures, though these were observed in patients with pre-existing risk factors and did not lead to treatment discontinuation. Other reported side effects include upper respiratory tract infections, vomiting, viral infections, and headaches.

Isembyld's Approval: Reshaping the SMA Treatment Landscape

The SMA treatment landscape has undergone a fundamental transformation over the past five years, driven by the clinical validation of three approved disease-modifying therapies: nusinersen, risdiplam, and onasemnogene abeparvovec. Each targets SMN protein production through distinct mechanisms — nusinersen and risdiplam modify SMN2 pre-mRNA splicing, while onasemnogene abeparvovec delivers functional SMN1 gene copies via viral-mediated gene therapy. Phase 3 trial data have firmly established the clinical efficacy of all three agents. The STR1VE trial demonstrated that 13 of 22 patients with SMA type 1 achieved independent sitting for 30 seconds or longer at 18 months, and 20 of 22 survived free from permanent ventilation at 14 months, compared with 6 of 23 in an untreated historical cohort (p<0.0001). The SUNFISH part 2 trial showed risdiplam produced a statistically significant improvement in 32-item Motor Function Measure total score versus placebo at month 12 (treatment difference: 1.55, 95% CI 0.30–2.81, p=0.016) in patients aged 2–25 years with type 2 or non-ambulant type 3 SMA. The EMBRACE study confirmed nusinersen's favorable long-term benefit-risk profile, with motor milestone responder rates of 93% in nusinersen-treated patients at last available assessment.

Long-term and real-world data have further refined the understanding of these therapies. The 5-year FIREFISH open-label extension demonstrated that after 5 years of risdiplam treatment, 56 of 62 enrolled children (90%) were alive and 50 (80%) were alive without the need for permanent ventilation, with upward trajectories in motor function observed between years 1 and 5. The RAINBOWFISH study of presymptomatic risdiplam treatment showed that after 12 months, 21 of 26 enrolled infants (81%) could sit unsupported for 30 seconds, 14 (54%) could stand alone, and 11 (42%) could walk alone, with all 23 infants completing 24 months of treatment alive without permanent ventilation or feeding support. Real-world data from the RESTORE registry in Japan, covering 80 patients treated with onasemnogene abeparvovec, reported event-free survival at 3 years of 93.0%, with 64.1% of patients with two or more developmental milestones achieving new developmental milestones. The SMART phase 3b study extended the evidence base for onasemnogene abeparvovec to patients weighing 8.5–21 kg, with 16 of 18 and 15 of 17 participants maintaining or improving motor function on the Hammersmith Functional Motor Scale-Expanded and Revised Upper Limb Module, respectively, by week 52.

A critical and consistent finding across all published trial data is that early intervention — particularly in the presymptomatic period — is associated with substantially better treatment outcomes, with some patients achieving normal or near-normal motor development. This principle has accelerated interest in newborn screening programs and has prompted investigation of combination and sequential therapy strategies. A 2025 systematic review of 19 studies and 6 ongoing clinical trials identified 29 individual patients receiving dual or triple combination regimens; these were generally well-tolerated with no consistent evidence of additive toxicity, though long-term efficacy remains uncertain. Switching therapies — particularly from nusinersen or risdiplam to onasemnogene abeparvovec — were the most common combination approach, reflecting the clinical reality that monotherapy may not halt disease progression in all patients. Robust long-term trials are described as essential to determine optimal sequencing, true long-term efficacy, and broader systemic benefits of these emerging combination strategies.

Addressing Unmet Needs in SMA with Muscle-Targeted Therapy

Despite the availability of three approved disease-modifying therapies for spinal muscular atrophy (SMA), significant gaps in care persist across multiple patient populations and clinical scenarios. Recent literature highlights a convergence of unmet needs spanning early diagnosis, residual motor deficits in treated patients, and underserved subgroups such as preterm infants and older or more severely affected patients.

• Residual motor deficits in patients already on approved SMN-targeting therapies. Approved SMA therapies greatly improve clinical outcomes; however, substantial motor function deficits persist. Apitegromab, a fully human monoclonal antibody that selectively inhibits myostatin activation, has been investigated in the SAPPHIRE phase 3 trial and the TOPAZ phase 2 study specifically to address this gap in nonambulatory type 2 and type 3 SMA patients receiving background nusinersen or risdiplam therapy.

• Newborn and presymptomatic populations requiring timely screening and treatment. Pre-symptomatic treatment markedly improves motor function development, underscoring the urgent need for large-scale newborn screening to prevent diagnostic delays and ensure timely, effective therapy. Data from the Campania region of Italy (62,801 infants screened) and from German NBS programmes both demonstrate that validated care protocols must be established to facilitate early diagnosis and intervention, including for preterm infants for whom national and international treatment recommendations are currently unavailable.

• Preterm infants with SMA, a population without standardised treatment guidance. Premature infants with SMA require interdisciplinary care in close collaboration with neuromuscular centres. National and international recommendations for treating preterm infants and newborns under 38 weeks of gestational age are unavailable, representing a distinct and underserved population identified through NBS implementation in Germany.

• Patients requiring treatment switching or sequential therapy. Real-world data from Croatia and the SMArtCARE registry indicate that a meaningful proportion of patients switch between disease-modifying treatments for clinical or personal reasons. Data on combination or sequential treatment with disease-modifying drugs are missing and the field is poorly understood, representing an unmet need for evidence-based guidance on treatment sequencing across SMA types and age groups.

• Older and more severely affected patients with longer diagnostic delays. In Brazil, time from symptom onset to genetic confirmation was longer in type 3 SMA patients, and earlier symptom onset combined with longer disease duration was associated with worse motor outcomes. Findings from the Brazilian and Saudi Arabian real-world cohorts reveal the clinical heterogeneity of SMA and emphasise the impact of diagnostic delays and disease duration on function, highlighting the need for early diagnosis and ongoing multidisciplinary care in these populations.

Understanding the Safety Profile of Apitegromab (Isembyld)

Across clinical studies from phase 1 through phase 3, apitegromab has demonstrated a consistent and generally favorable safety and tolerability profile, with no treatment-related deaths or serious adverse reactions reported in the phase 2 TOPAZ study and no patient discontinuations due to adverse events in the phase 3 SAPPHIRE trial.

• Phase 1 (healthy adult subjects): Single and multiple ascending intravenous doses (1–30 mg/kg) were safe and well tolerated, with no clinically meaningful changes in vital signs, electrocardiograms, or clinical laboratory parameters, and no anti-drug antibody formation observed.

• Phase 2 TOPAZ (12-month primary analysis): The 5 most frequently reported treatment-emergent adverse events were headache (24.1%), pyrexia (22.4%), upper respiratory tract infection (22.4%), cough (22.4%), and nasopharyngitis (20.7%). No deaths or serious adverse reactions were reported across the 58 enrolled participants.

• Phase 2 TOPAZ (36-month open-label extension, nonambulatory patients): The most frequently reported treatment-emergent adverse events were pyrexia (48.6%), nasopharyngitis (45.7%), COVID-19 infection (40.0%), vomiting (40.0%), and upper respiratory tract infection (31.4%), with no new safety findings identified relative to the 12-month data.

• Phase 3 SAPPHIRE (nonambulatory type 2 or type 3 SMA): The incidence and severity of adverse events were similar between apitegromab and placebo groups, and consistent with spinal muscular atrophy and background spinal muscular atrophy therapy. The most frequently reported adverse events were pyrexia (apitegromab 26% vs. placebo 28%), nasopharyngitis (25% vs. 23%), cough (23% vs. 20%), vomiting (23% vs. 17%), upper respiratory tract infection (22% vs. 30%), and headache (21% vs. 20%). No patients discontinued due to adverse events.

Isembyld's Approval: A New Chapter for SMA Combination Therapy

The recent FDA approval of Isembyld (apitegromab) for spinal muscular atrophy (SMA) marks a pivotal moment, introducing the first muscle-targeted therapy to an evolving treatment landscape. This approval is particularly significant because Isembyld, which inhibits myostatin to promote muscle growth, is intended for use alongside existing SMN-enhancing therapies. While current treatments have dramatically improved outcomes for SMA patients, they do not fully reverse the progressive muscle atrophy and motor function deficits. Isembyld directly addresses this residual burden by focusing on muscle preservation and growth.

Clinical data from the Phase 2 TOPAZ and Phase 3 SAPPHIRE trials underscore the potential of this approach. The TOPAZ study demonstrated improved or stabilized motor function in patients with Type 2 and Type 3 SMA, with benefits sustained over 36 months and a favorable safety profile. The SAPPHIRE trial further supported these findings, showing statistically significant improvements in motor function for the combined apitegromab dose groups compared to placebo in nonambulatory patients already on SMN-targeting therapies. This evidence points to a future where combination regimens become the standard, leveraging both SMN protein restoration and direct muscle enhancement to maximize patient potential.

However, the path forward is not without considerations. While the combined dose in SAPPHIRE was significant, the 20 mg/kg dose alone did not reach statistical significance against placebo, suggesting that optimal dosing strategies or patient stratification may require further refinement. Furthermore, the annual list price of $310,000 for an add-on therapy will undoubtedly prompt discussions with payers regarding its value proposition and access, especially given the already high cost of SMA care. Common adverse events, though generally mild, will also need careful management in this patient population. Despite these challenges, Isembyld's approval represents a crucial step towards a more comprehensive treatment strategy for SMA, offering renewed hope for improved motor function and quality of life for patients.